Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CABA 
Cabaletta Bio Inc (CABA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CABA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $11.56
1 Year Target Price $11.56
| 8 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.14% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 137.20M USD | Price to earnings Ratio - | 1Y Target Price 11.56 |
Price to earnings Ratio - | 1Y Target Price 11.56 | ||
Volume (30-day avg) 12 | Beta 2.74 | 52 Weeks Range 0.99 - 5.83 | Updated Date 08/28/2025 |
52 Weeks Range 0.99 - 5.83 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.71 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.6499 | Actual -0.73 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.39% | Return on Equity (TTM) -76.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -32591151 | Price to Sales(TTM) - |
Enterprise Value -32591151 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.44 | Shares Outstanding 91465200 | Shares Floating 61644823 |
Shares Outstanding 91465200 | Shares Floating 61644823 | ||
Percent Insiders 1.65 | Percent Institutions 79.8 |
Upturn AI SWOT
Cabaletta Bio Inc
Company Overview
History and Background
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring new approaches to B cell-mediated autoimmune diseases. Founded in 2017, Cabaletta Bio aims to develop targeted and potentially curative therapies for patients with B cell-mediated autoimmune diseases.
Core Business Areas
- Engineered T Cell Therapies: Cabaletta Bio's primary focus is the development of engineered T cell therapies, specifically Chimeric AutoAntibody Receptor T cells (CAAR T), designed to selectively eliminate pathogenic B cells in autoimmune diseases.
- Preclinical Research: The company engages in preclinical research to identify new CAAR T targets and expand its pipeline of therapies for various autoimmune indications.
- Clinical Development: Cabaletta Bio conducts clinical trials to evaluate the safety and efficacy of its CAAR T therapies in patients with autoimmune diseases such as myasthenia gravis (MG), pemphigus vulgaris (PV), and systemic lupus erythematosus (SLE).
Leadership and Structure
Steven Kelly serves as the President and CEO. The company has a management team overseeing research, clinical development, and business operations. The structure follows a typical biotech model with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- DSG3-CAART (CABA-201): This is a CAAR-T cell therapy targeting DSG3 expressing B cells in Pemphigus Vulgaris (PV). It is in clinical development. There is currently no market share data. Competitors include companies developing other therapies for PV, such as anti-CD20 antibodies (rituximab). Major competitors are Roche and Argenx, who has Vyvgart.
- MuSK-CAART (CABA-301): This is a CAAR-T cell therapy targeting MuSK expressing B cells in Myasthenia Gravis (MG). It is in clinical development. There is currently no market share data. Competitors include companies developing other therapies for MG, such as anti-FcRn antibodies (efgartigimod). Major competitor is Argenx with Vyvgart, and Johnson and Johnson and UCB with anti-FcRn therapies
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is large and growing, with significant unmet needs for more effective and durable treatments. It involves a variety of biologicals and small molecules. CAAR-T is aiming for cure which existing products cannot provide.
Positioning
Cabaletta Bio is positioned as an innovator in the autoimmune disease space, focusing on CAAR-T cell therapies. It aims to provide targeted and potentially curative treatments compared to existing symptomatic therapies.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapeutics is estimated to be over $100 billion. Cabaletta Bio is focused on specific subsets of autoimmune diseases where CAAR-T cell therapy has the potential to provide a curative benefit, addressing a substantial portion of the overall market. PV and MG themselves represent multi-billion dollar markets.
Upturn SWOT Analysis
Strengths
- Novel CAAR-T cell technology platform
- Targeted approach to B cell-mediated autoimmune diseases
- Strong intellectual property position
- Experienced management team
Weaknesses
- Early stage clinical development
- High development costs associated with cell therapies
- Dependence on clinical trial success
- Potential for off-target effects or toxicity
Opportunities
- Expansion of CAAR-T platform to other autoimmune diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
- Potential for breakthrough therapy designation
Threats
- Competition from existing therapies
- Regulatory hurdles
- Clinical trial failures
- Adverse events in clinical trials
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- ARGN (Argenx)
- RHHBY (Roche Holding AG)
Competitive Landscape
Cabaletta Bio is focused on CAAR-T therapy, while competitors often have broader portfolios. Cabaletta Bio has the advantage of curative potential compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing its CAAR-T programs through preclinical and clinical development.
Future Projections: Future growth is dependent on clinical trial successes and potential regulatory approvals.
Recent Initiatives: Advancing clinical trials for CABA-201 and CABA-301, expanding preclinical research into new CAAR-T targets.
Summary
Cabaletta Bio is a biotechnology company focused on CAAR-T cell therapies for autoimmune diseases, holding a promising technology platform. Currently the company is relatively weak, being in early-stage clinical development. It is dependent on clinical trial success. Cabaletta Bio needs to watch out for regulatory hurdles and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on available information and should not be considered financial advice. The information provided is for informational purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cabaletta Bio Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2019-10-25 | Co-Founder, Chairman, CEO & President Dr. Steven A. Nichtberger M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 167 | Website https://www.cabalettabio.com |
Full time employees 167 | Website https://www.cabalettabio.com | ||
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.